Nanomedicine for Brain Delivery of Monoclonal Antibodies: The Impact of Nanocarrier Structure

Introduction: Monoclonal antibodies (mAbs) are potent therapeutics given its high specificity, prove of it is the increasing number of marketed mAbs [1,2]. Nanomedicine has emerged as a promising strategy for delivering biologics to the brain, particularly for overcoming the challenge of crossing the blood-brain barrier. However, ensuring effective mAb diffusion within brain tissue remains a critical hurdle. This study explores how nanomedicine can address this challenge by evaluating two nanosystems designed to enhance both brain diffusion and intracellular delivery of mAbs.

Inés Rubio-Prego – PhD student, University of Santiago de Compostela; Ana López-Estévez – Postdoctoral researcher, Istituto Italiano di Tecnologia; Ana Rodríguez-Pérez – Associate Professor, University of Santiago de Compostela; Rita Valenzuela – Assistant Professor, University of Santiago de Compostela; Pablo Garrido-Gil – Associate Professor, University of Santiago de Compostela; Noemí Gómez-Lado – Lab technician, University of Santiago de Compostela; María Medel – Postdoctoral researcher, Prince Felipe Research Center; María Vicent – Principal Investigator, Prince Felipe Research Center; José Labandeira-Garcia – Principal Investigator, University of Santiago de Compostela; Pablo Aguiar – Principal Investigator, University of Santiago de Compostela; María Alonso – Principal Investigator, University of Santiago de Compostela